Fig. 1

CYP2E1 Expression in myocardial mitochondria under various heart diseases. (A) CYP2E1 expression in left ventricular myocardial tissue from clinical dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) samples. Data were analyzed using GSE116250 dataset from GEO and presented as RPKM (Reads Per Kilobase per Million mapped reads); n = 14 for non-heart failure donor group, n = 37 for DCM group, and n = 13 for ICM group. (B) Schematic representation of animal model establishment and experimental strategy for analyzing expression characteristics. Abbreviations: DXR, doxorubicin; AngII, angiotensin II; ISO, isoprenaline. (C) CYP2E1 protein levels in total protein and mitochondrial protein extracts from cardiac tissues in the animal models, determined via immunoblotting. (D-E) Quantification of CYP2E1 expression in total and mitochondrial protein extracts, normalized to GAPDH or VDAC1. Data shown are mean ± SEM; n = 4 per group. (F) CYP2E1 distribution in myocardial tissue from DXR-induced myocardial injury rat model and ISO-induced myocardial hypertrophy rat model via immunofluorescence. Colocalization of CYP2E1 (red) and ATP5A (mitochondrial marker, green) is indicated by white arrows. DAPI (blue) and F-actin (purple) are used as nuclear and myocardial structure markers, respectively. Scale bars: 20 μm. Multiple comparisons were conducted using ANOVA with Tukey correction. Two-group comparisons were executed using unpaired two-tailed Student’s t-tests. *P < 0.05, **P < 0.01, ***P < 0.001